Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #6
Chicca, A; Schafroth, MA; Reynoso-Moreno, I; Erni, R; Petrucci, V; Carreira, EM; Gertsch, J. Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high. Sci. Adv., 1 Oct 2018, 4 (10), eaat2166. 4.7 MB. https://doi.org/10.1126/sciadv.aat2166 #2-Arachidonoyl glycerol LC,MS,NMR,IR,other
Banister, SD; Kumar, KK; Kumar, V; Kobilka, BK; Malhotra, SV. Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain. MedChemComm, 22 May 2019, 10 (5), 647–659. 810 kB. https://doi.org/10.1039/C8MD00595H #2
Banister, SD; Arnold, JC; Connor, M; Glass, M; McGregor, IS. Dark classics in chemical neuroscience: Δ9-Tetrahydrocannabinol. ACS Chem. Neurosci., 15 May 2019, 10 (5), 2160–2175. 1.8 MB. https://doi.org/10.1021/acschemneuro.8b00651 #14
Al-Zoubi; Morales; Reggio. Structural Insights into CB1 Receptor Biased Signaling. IJMS, 13 Apr 2019, 20 (8), 1837. 3.4 MB. https://doi.org/10.3390/ijms20081837 #2-AG